The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...

Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...

Homebuyers have won a significant victory as MahaREAT ruled a builder cannot use inter-authority disputes to justify possession delays exce...

As the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...

A gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Happy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Global economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...

As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...

Abakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

The most impactful AI products of 2026 aren't built to do everything; they're built to solve one problem exceptionally well. The ET Most In...

Indian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...